ARTICLE | Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

September 21, 2018 6:58 PM UTC

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases.

Jenrin will receive $250,000 upfront and is eligible for $18.4 million in milestones for each compound Corbus develops. Jenrin is also eligible for mid, single-digit royalties. Under the deal, Jenrin will not research, develop or commercialize any compounds modulating cannabinoid receptors for 10 years...